Naltrexone · Revia, Vivitrol

What is Naltrexone?

Naltrexone is an opioid antagonist with highest affinity for the mu opioid receptor, and it also binds kappa and gamma opioid receptors in the central nervous system, blocking the actions of opioid agonists.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Revia, Vivitrol, NSC-758439, XR-NTX

Drug type

Small molecule

Targets

mu opioid receptor (OPRM1), kappa opioid receptor (OPRK1) (secondary target), delta opioid receptor (OPRD1) (secondary target)

Mechanism

Antagonist of mu opioid receptor (OPRM1)

Pathways

opioid receptor signaling blockade

Therapy area

Psychiatry

Developer

Teva Womens

In trials of

ALKS, SCLX

FDA status

Approved as Revia, Vivitrol (November 20, 1984), NDA018932 · FDA label

UNII

5S6W795CQM

✅ FDA-approved uses

• Alcohol dependence (Vivitrol)
• Opioid dependence (Vivitrol)

From the indications section of the FDA label (version of May 31, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy VolunteersOpioid Use DisordersOpioid-Related Disorders

Other drugs acting on OPRM1

Sources

• FDA label (DailyMed)
• FDA label Vivitrol (2026-05-31), indications
• FDA label Naltrexone (2026-01-30), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT02110264
• ClinicalTrials.gov NCT02978417
• ClinicalTrials.gov NCT02978417

Updated Oct 11, 2026.